Biogen Idec 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report:
August 9, 2005
(Date of earliest event reported)
Biogen Idec Inc.
(Exact Name of Registrant as Specified in Charter)
14 Cambridge Center
Cambridge, Massachusetts 02142
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
TABLE OF CONTENTS
Item 8.01. OTHER EVENTS.
On August 9, 2005, Biogen Idec Inc. publicly disseminated a press release announcing an update of its safety evaluation of TYSABRI® (natalizumab). The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.